FDA-approved Therapies for Geographic Atrophy

Opinion
Video

An expert retina specialist discusses the recent FDA-approved treatments for geographic atrophy (GA) that slow disease progression and highlights key factors to consider before starting treatment.

Recent Videos
Video 4 - "Treating Geographic Atrophy in Patients with Concurrent Neovascular AMD"
Video 3 - "Managing a Patient with Bilateral Geographic Atrophy"
Video 1 - "Geographic Atrophy: Overview, Diagnosis, and Progression"
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
Related Content
Akari Therapeutics receives “positive and constructive” pre- Investigational New Drug for PAS-nomacopan

Akari Therapeutics receives “positive and constructive” pre- Investigational New Drug for PAS-nomacopan

Martin David Harp
August 20th 2024
Article
Spotlighting telemedicine in the year of a pandemic

Spotlighting telemedicine in the year of a pandemic

Alex Delaney-Gesing
October 19th 2020
Podcast
M. Roy Wilson, MD, touches upon reconceptualizing the use of race in medicine as part of his Robert Copeland Distinguished Lecture at the National Medical Association's annual conference in New York City, NY.

NMA 2024: M. Roy Wilson, MD, touches upon reconceptualizing the use of race in medicine

Sheryl Stevenson
August 3rd 2024
Article
Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410

Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410

David Hutton
July 26th 2024
Article
Ophthalmology researchers develop framework to reduce spin in scientific reporting

Ophthalmology researchers develop framework to reduce spin in scientific reporting

David Hutton
July 22nd 2024
Article
European Union’s Committee for Medicinal Products for Human Use issues negative opinion on Apellis’ pegcetacoplan (Syfovre) injection

European Union’s Committee for Medicinal Products for Human Use issues negative opinion on Apellis’ pegcetacoplan (Syfovre) injection

Martin David Harp
July 4th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.